GlassScriptPhysician profile
Heather Reagin
NPI 1407260151
$15,416.71
in general payments reported to CMS, 2019-2025
35 companies · $3,212 in 2025
The $3,212 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,800 · 2020: $498 · 2021: $751 · 2022: $2,885 · 2023: $2,826 · 2024: $3,445 · 2025: $3,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,399 · Education: $83.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,398.58 |
| Education | $83.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,915.33 | 2019-2025 | |
| Epi Health, LLC | $1,500.00 | 2022 | |
| Genzyme Corporation | $1,239.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,126.43 | 2020-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $1,023.37 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $1,001.51 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $962.54 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $802.74 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $795.75 | 2019-2025 | |
| Galderma Laboratories, L.P. | $588.55 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $542.22 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $426.73 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $367.43 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Merz North America, INC. | $354.17 | 2023-2025 | Xeomin |
| Celgene Corporation | $326.28 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $323.22 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $280.16 | 2021-2025 | |
| Ucb, INC. | $271.04 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $211.18 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $206.32 | 2021-2024 | Adbry |
| Allergan, INC. | $203.30 | 2019-2022 | |
| Journey Medical Corporation | $135.15 | 2020-2025 | |
| Almirall LLC | $131.69 | 2019-2025 | Klisyri, Seysara |
| Janssen Scientific Affairs, LLC | $100.97 | 2019 | |
| Botanix Sb INC | $90.12 | 2025 | Sofdra |
| Biofrontera INC. | $86.16 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Glenmark Therapeutics INC. | $78.00 | 2019 | |
| Encore Dermatology INC. | $68.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.68 | 2023-2025 | Spevigo |
| Organon LLC | $63.61 | 2025 | Vtama |
| Amgen INC. | $36.94 | 2022-2025 | Otezla |
| Mimedx Group, INC. | $32.97 | 2024 | |
| Novum Pharma, LLC | $29.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Lnhc, INC | $13.86 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Reagin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.